Marken Announces the Opening of a Directly Owned Clinical Trial Supply Depot in Singapore.
Marken has increased presence and capability in Singapore.
As part of Marken’s continued expansion of services in the APAC region, they have relocated and expanded their Singapore office to further support clients’ needs for specialty logistics services. This expansion incorporates a new directly owned, purpose-built Singapore depot to support growing customer demand for Investigational Medical Product distribution.
The new GMP compliant facility enables clients to leverage Marken’s global expertise in Life Science logistics while adding key Life Science specialty services for their programs in the Asia Pacific and Middle East regions. In recent presentation to Marken employees, Gerard Barba, CEO of Marken announced “ The opening of our directly owned depot in Singapore sets the corner stone of an expanding global network of GMP compliant distribution centers for Marken. “
The new 14,500 sq. ft. Clinical Trial Supply Depot offers the full range of secured storage conditions including
- Secured Controlled Drug (ambient)
- 15 – 25C (controlled ambient)
- -2- 8C (cold storage)
- -20C (frozen)
- -80C (deep frozen)
Clinical Trial Logistics services offered:
- Storage and distribution
- Drug returns and destruction
- Kit building
- Biological specimen storage in ultra low freezers – short and long term
The expanded Marken office in Singapore provides Life Science material logistics and Clinical Trial Supply management for Pharmaceutical and Biotech customers throughout the Asia Pacific region. This represents Marken's latest investment in the region, which in 2010 saw the opening of a new office in Tokyo.s
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
